Timothy G. Youngquist 2020 Irrevocable Trust’s Mineralys Therapeutics MLYS Stock Holding History

Timothy G. Youngquist 2020 Irrevocable Trust’s Portfolio MLYS Stock Details MLYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.72M	Buy	+100,869	New	+$2.77M	0.53%	23

Other funds holding MLYS

Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Andera Partners Paris $206M AUM

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

TCM

TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

Timothy G. Youngquist 2020 Irrevocable Trust's MLYS Position: Q2 2026 in Review

Timothy G. Youngquist 2020 Irrevocable Trust opened a new position in Mineralys Therapeutics (MLYS) in Q2 2026: 100,869 shares worth $2.72M. The stake represents 0.53% of the portfolio and ranks #23 among its holdings.

58 funds tracked by Wall St. Rank hold MLYS as of Q2 2026.

Timothy G. Youngquist 2020 Irrevocable Trust held 100,869 shares of Mineralys Therapeutics worth $2.72M as of Q2 2026.
Mineralys Therapeutics was a new Timothy G. Youngquist 2020 Irrevocable Trust position in Q2 2026.
Mineralys Therapeutics made up 0.53% of Timothy G. Youngquist 2020 Irrevocable Trust's portfolio in Q2 2026, its #23 holding.
58 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2026.

Based on Timothy G. Youngquist 2020 Irrevocable Trust's 13F filing for Q2 2026, filed 7 Aug 2026.